Neonatal screening for congenital hypothyroidism has been effective in early detection and treatment of the condition. The position with respect to neonatal screening for congenital adrenal hyperplasia has been debated for many years. Some countries have performed congenital adrenal hyperplasia screening for many years, others have conducted pilot studies that were then not adopted. This article endeavours to summarize the complex issues behind decisions whether to screen or not and summarizes the findings of neonatal congenital adrenal hyperplasia screening programmes.

1.
Hughes IA: Congenital adrenal hyperplasia – a continuum of disorders: Lancet 1998;352:752–754.
2.
Allen DB, Farrell PM: Newborn screening: Principles and practice. Adv Pediatr 1996;43:231–270.
3.
Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, Riley WJ: Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999;153:1272–1278.
4.
Virdi NK, Green A: Congenital adrenal hyperplasia in Britain: A retrospective analysis (1958–1985). J Inherit Metab Dis 1986;9:152–155.
5.
Pang S, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon ICT, Dobbins RH, Kling S, Fujeida K, Suwa S: Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988;81:866–874.
6.
Pang S, Clark A: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993;2:105–139.
7.
Torresani T, Grueters A, Scherz R, Burckhardt JJ, Harras A, Zachmann M: Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17α-hydroxyprogesterone to gestational age. Screening 1994;3:77–84.
8.
Cutfield WS, Webster D: Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995;126:118–121.
9.
Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, Zappulla F: Congenital adrenal hyperplasia: Neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy 1980–1995. Pediatrics 1996;98:362–367.
10.
Webster D, Essex C: Neonatal screening in New Zealand. BMJ 1996;312:312.
11.
Toublanc JE, Nivelon JL, Morel Y: Dépistage de l’hyperplasie surrénale congénitale par deficit en 21-hydroxylase. Expérience de l’Association Française pour le Dépistage et la Prévention des Handicaps de l’Enfant. In: Journées Parisiennes de Pédiatrie. Paris, Flammarion Médecine-Sciences, 1996, pp 181–189.
12.
Sack J, Front H, Kaiserman I, Schreiber M: 21-Hydroxylase deficiency: Screening and incidence in Israel. Horm Res 1997;48:115–119.
13.
Therrell BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S: Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101:583–590.
14.
Thilen A, Nordenstrom A, Hagenfeldt L, von Dobein U, Guthenberg C, Larsson A: Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998;101:e11.
15.
Chin D, Speiser PW, Imperato-McGinley J, Dixit N, Uli N, David R, Oberfield SE: Study of a kindred with classic congenital adrenal hyperplasia: Diagnostic challenge due to phenotypic variance. J Clin Endocrinol Metab 1998;83:1940–1945.
16.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna M-T: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584–595.
17.
Mornet E, Crete P, Kuttenn F: Distribution of deletions and seven point mutations on CYP21 genes in the three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet 1991;48:79–88.
18.
Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: Implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994;71:1145–1152.
19.
Pang S, Hotchkiss J, Drash AL, Levine LS, New MI: Microfilter paper methods for 17-hydroxyprogesterone radioimmunoassay: Its application for rapid screening of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977;45:1003–1008.
20.
Wong T, Shackleton CHL, Covey TR, Ellis G: Identification of the steroids in neonatal plasma that interfere with 17-hydroxyprogesterone radioimmunoassays. Clin Chem 1992;38:1830–1837.
21.
Mitchell ML, Hermos RJ: Cortisol in dried blood screening specimens with raised 17-hydroxyprogesterone and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1998;48:757–560.
22.
Kelnar CJH: Congenital adrenal hyperplasia (CAH) – the place for prenatal treatment and neonatal screening. Early Hum Dev 1993;35:81–90.
23.
Streetly A, Grant C, Pollitt RJ, Addison GM: Survey of scope of neonatal screening in the United Kingdom. BMJ 1995;311:726.
24.
Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology: Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism. Horm Res 1999;52:49–52.
25.
Wallace AM, Beesley J, Thomson M, Ross AM, Taylor NF: Adrenal status during the first month of life in term and immature infants. J Endocrinol 1987;12:473–480.
26.
Al-Saedi S, Dean H, Dent W, Stockl E, Cronin C: Screening for congenital adrenal hyperplasia: The Delfia screening test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics 1996;97:100–102.
27.
Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A: Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997;130:128–133.
28.
Listernick R, Frisone L, Silverman BL: Delayed diagnosis of infants with abnormal neonatal screens. JAMA 1992;267:1095–1099.
29.
Donaldson MD, Thomas PH, Love JG, Murray GD, McNinch AW, Savage DCL: Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency. Arch Dis Child 1994;70:214–218.
30.
Honour JW, Brook CGD: Clinical indications for urinary steroid profile analysis in neonates and children. Ann Clin Biochem 1997;34:45–54.
31.
Wilson RC, Mercado AB, Cheng KC, New MI: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80:2322–2329.
32.
Nordenstrom A, Thilen A, Hagenfeldt L, Larsson A, Wedell A: Genotyping is a valuable complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999;84:1505–1509.
33.
Witchel SF, Nayak S, Suda-Hartman M, Lee PA: Newborn screening for 21-hydroxylase deficiency: Results of CYP21 molecular genetic analysis. J Pediatr 1997;131:328–331.
34.
New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS: Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab 1983;57:320–326.
35.
Brosnan CA, Brosnan P, Therell BL, Annegers JF, Riley WJ: A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas. Public Health Rep 1998;113:170–178.
36.
Xu Y-Y, Pettersson K, Blomberg K, Hemmila I, Mikola H, Lovgren T: Simultaneous quadruple-label fluorometric immunoassay of thyroid-stimulating hormone, 17α-hydroxyprogesterone, immunoreactive trypsin and creatinine kinase MM isoenzyme in dried blood spots. Clin Chem 1992;38:2038–2043.
37.
Swerdlow AJ, Higgins CD, Brook CG, Dunger DB, Hindmarsh PC, Price DA, Savage MO: Mortality in patients with congenital adrenal hyperplasia: A cohort study. J Pediatr 1998;133:516–520.
38.
Thomason MJ, Lord J, Bain MD, Chalmers RA, Littlejohns P, Addison GM, Wilcox AH, Seymour CA: A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Public Health Med 1998;20:331–343.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.